These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15473024)

  • 21. [Cetuximab].
    Takiuchi H
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1192-5. PubMed ID: 17687200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
    Owzar K
    J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
    [No Abstract]   [Full Text] [Related]  

  • 23. Progress in the development of novel treatments for colorectal cancer.
    Hoff PM; Pazdur R
    Oncology (Williston Park); 2004 May; 18(6):705-8. PubMed ID: 15214591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
    J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
    J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Improving longevity in advanced intestinal cancer].
    Schmoll HJ
    Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan.
    Ku GY; Krol G; Ilson DH
    J Clin Oncol; 2007 May; 25(13):e14-6. PubMed ID: 17470852
    [No Abstract]   [Full Text] [Related]  

  • 29. Erbitux trial flawed from the beginning, committee finds.
    Randal J
    J Natl Cancer Inst; 2002 Dec; 94(24):1824-5. PubMed ID: 12488469
    [No Abstract]   [Full Text] [Related]  

  • 30. [A case of rectal cancer with lung metastases responding to cetuximab].
    Kawai H; Uetake H; Kobayashi H; Enomoto M; Higuchi T; Yasuno M; Iida S; Ishikawa T; Sugihara K
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2152-4. PubMed ID: 20037353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
    Sørbye H; Braendengen M; Balteskard L
    Tidsskr Nor Laegeforen; 2008 Jan; 128(2):194-7. PubMed ID: 18202732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Dohn LH; Jensen BV; Larsen FO
    Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
    Jackson C; Cunningham D
    Eur J Cancer; 2008 Mar; 44(5):652-62. PubMed ID: 18313913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acneiform eruption following molecular targeted chemotherapy.
    Vaccaro M; Barbuzza O; Pollicino A; Guarneri C
    Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168
    [No Abstract]   [Full Text] [Related]  

  • 36. [New therapy options in colorectal carcinoma].
    Folprecht G; Köhne CH
    Ther Umsch; 2004 Jun; 61(6):373-8. PubMed ID: 15253162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
    Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
    Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cetuximab plus irinotecan in refractory colorectal cancer patients.
    Gil Delgado M; Spano JP; Khayat D
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):407-13. PubMed ID: 17428161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
    Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.